Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Hydrogen Sulfide and H2S Donors in Cardiovascular, Metabolic,...
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Hydrogen Sulfide and H2S Donors in Cardiovascular, Metabolic, and Inflammatory Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 1279

Special Issue Editors

Dr. Alma Martelli

E-Mail Website
Guest Editor
1. Department of Pharmacy, University of Pisa, 56126 Pisa, Italy
2. Interdepartmental Research Centre "Nutraceuticals and Food for Health (NUTRAFOOD)", University of Pisa, 56126 Pisa, Italy
3. Interdepartmental Research Centre of "Ageing Biology and Pathology", University of Pisa, 56126 Pisa, Italy
Interests: cardiovascular pharmacology; gasotransmitters; nutraceuticals; hydrogen sulfide; brassicaceae; isothiocyanates; vascular inflammation; aging; endothelial dysfunction; hypertension; H2S-donors
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Vincenzo Calderone

E-Mail Website
Guest Editor
Department of Pharmacy, University of Pisa, Via Bonanno Pisano 6, 56126 Pisa, Italy
Interests: H2S; gasotransmitters; cardiovascular pharmacology; ion channels; metabolic pharmacology; synthetic and natural H2S donors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hydrogen sulfide (H2S) is a pleiotropic endogenous gasotransmitter able to maintain homeostasis in several systems. In recent years, the discovery that the physiological production of H2S resulted in the impairment of several pathological conditions such as hypertension, diabetes, endothelial dysfunction, etc., led to the study of exogenous sources of H2S that are able to compensate for the lack or imbalance of H2S, which are called H2S donors. In this Special Issue, we focus our attention on the role of H2S and /or H2S donors in the physiopathological aspects of cardiovascular, metabolic or inflammatory diseases (including degenerative pathologies derived from the persistence of a chronic subclinical inflammation, such as cancer and neurodegenerative diseases). The demonstration or the speculation about the mechanisms of action by which H2S and H2S donors act in different pathologies will also be appreciated. Finally, the synthesis or the identification of novel natural H2S donors will also be considered of interest for our Special Issue.

Dr. Alma Martelli
Prof. Dr. Vincenzo Calderone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hydrogen sulfide
  • H2S-donors
  • cardiovascular diseases
  • metabolic diseases
  • inflammatory diseases
  • cancer
  • neurodegenerative diseases

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 5660 KiB  
Article
Anti-Proliferative Properties of the Novel Hybrid Drug Met-ITC, Composed of the Native Drug Metformin with the Addition of an Isothiocyanate H2S Donor Moiety, in Different Cancer Cell Lines
by Valentina Citi, Elisabetta Barresi, Eugenia Piragine, Jacopo Spezzini, Lara Testai, Federico Da Settimo, Alma Martelli, Sabrina Taliani and Vincenzo Calderone
Int. J. Mol. Sci. 2023, 24(22), 16131; https://doi.org/10.3390/ijms242216131 - 09 Nov 2023
Cited by 1 | Viewed by 954
Abstract
Metformin (Met) is the first-line therapy in type 2 diabetes mellitus but, in last few years, it has also been evaluated as anti-cancer agent. Several pathways, such as AMPK or PI3K/Akt/mTOR, are likely to be involved in the anti-cancer Met activity. In addition, [...] Read more.
Metformin (Met) is the first-line therapy in type 2 diabetes mellitus but, in last few years, it has also been evaluated as anti-cancer agent. Several pathways, such as AMPK or PI3K/Akt/mTOR, are likely to be involved in the anti-cancer Met activity. In addition, hydrogen sulfide (H2S) and H2S donors have been described as anti-cancer agents affecting cell-cycle and inducing apoptosis. Among H2S donors, isothiocyanates are endowed with a further anti-cancer mechanism: the inhibition of the histone deacetylase enzymes. On this basis, a hybrid molecule (Met-ITC) obtained through the addition of an isothiocyanate moiety to the Met molecule was designed and its ability to release Met has been demonstrated. Met-ITC exhibited more efficacy and potency than Met in inhibiting cancer cells (AsPC-1, MIA PaCa-2, MCF-7) viability and it was less effective on non-tumorigenic cells (MCF 10-A). The ability of Met-ITC to release H2S has been recorded both in cell-free and in cancer cells assays. Finally, its ability to affect the cell cycle and to induce both early and late apoptosis has been demonstrated on the most sensitive cell line (MCF-7). These results confirmed that Met-ITC is a new hybrid molecule endowed with potential anti-cancer properties derived both from Met and H2S. Full article
(This article belongs to the Special Issue Hydrogen Sulfide and H2S Donors in Cardiovascular, Metabolic, and Inflammatory Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop